export_upper respiratory viruses ii Flashcards
Influenza virus family and characteristics
Orthomyxovirus (-ssRNA)
Segmented genome
Enveloped
Hemagglutinin and neuraminidase
Hemagluttinin
Attachment
Agglutinates RBC
Neuraminidase
Cleaves sialic acid
Virion release
Virion spread
Two important clinical features for influenza virus
Ag drift
Ag shift
Ag drift
Small changes in hemagluttinin and neuraminidase, driven by point mutations
Changes every 2-3 years
Ag shift
Large changes to hemagluttinin and neuraminidase, driven by reassortment of two viruses
Co-infection of the same cell
Where does the most dangerous reassortment of influenza occur?
When an organism is coinfected from two different sources (a pig infected with human and duck influenza viruses) This organism (mixing vessel) can result in reassortment, that can the re-infect the human with a new flu virus that has never been seen by the immune system
Influenza A genome segments
8
Influenza A host
Humans, swine, avian, equines, marine mammals
Influenza A severity
Often severe
Influenza A epidemic potential
Often epidemics, pandemics
Influenza A Ag change
Ag drift AND
Ag shift
Influenza B genome segments
8
Influenza B hosts
Human
Influenza B severity
Occasionally severe
Influenza B epidemic potential
Outbreaks, occasional epidemics
Influenza B Ag change
ONLY Ag drift
Influenza C genome segments
7
Influenza C hosts
Humans, swine
Influenza C severity
Usually mild
Influenza C epidemic potential
Limited outbreaks
Influenza C Ag change
ONLY Ag drift
How do you name influenza viruses?
Serotype/location/isolates/year(H-serotypeNserotype)
Ex: A/Texas/1/77(H3N2)
Treatment for a mild/uncomplicated virus with NO risk factors
May consider antiviral within 48 hours
Symptomatic care, infection control
Return for care if no improvement in 72 hours
Treatment for a mild/uncomplicated virus WITH risk factors
Treat with antiviral
Close follow-up
Symptomatic care and infection control
Return if no improvement within 72 hours
Anti-virals
Ion channel blockers
Blocks replication prior to genome release
Only effective against Influenza A, but currently circulating A strains are resistant
Amantadine and Rimantadine
Anti-viral ion channel blockers
Neuraminidase inhibitor examples
Zanamivir (Relenza)
Oseltamivir (Tamiflu)
Peramivir (Repivab)
Zanamivir administration
Oral inhalation